Divalent Chalcogen Or Acyclic Nitrogen Double Bonded Directly At Both 2- And 4- Positions, Or Tautomeric Equivalent (e.g., Hydantoin, Etc.) Patents (Class 514/389)
-
Publication number: 20140073639Abstract: The application describes targets and methods that can inhibit bacterial growth in Gram-positive and Gram-negative bacteria. A bacterial enzyme, 2-epimerase, is common to both Gram-positive and Gram-negative bacteria and contains an allosteric site that can be targeted to disrupt the enzyme. The allosteric site is present on the bacterial 2-epimerase, but the analogous mammalian enzyme does not contain the allosteric site, providing a route for attacking bacterial infections without affecting the mammalian enzyme.Type: ApplicationFiled: August 8, 2013Publication date: March 13, 2014Applicants: The Rockefeller University, Avacyn Pharmaceuticals, Inc.Inventors: Vincent A. FISCHETTI, Allan R. GOLDBERG, Raymond SCHUCH
-
Publication number: 20140073611Abstract: The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.Type: ApplicationFiled: May 21, 2013Publication date: March 13, 2014Applicant: National Taiwan UniversityInventors: I-Jong Wang, Wei-Ting Ho, Ting-Hsuan Chiang, I-Tsen Lin
-
Publication number: 20140066443Abstract: The present invention is directed to aminomethyl biaryl benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.Type: ApplicationFiled: April 30, 2012Publication date: March 6, 2014Inventors: Douglas C. Beshore, Robert M. Garbaccio, Scott D. Kuduk, Adam W. Johnson, Jason W. Skudlarek
-
Publication number: 20140066466Abstract: Described herein are compositions that inhibit the production of TNF? downstream of CD40 activation. As such, also described are various methods of using compositions exhibiting this activity for the treatment or prevention of inflammatory diseases associated with TNF? production or CD40 activation.Type: ApplicationFiled: March 12, 2012Publication date: March 6, 2014Applicant: President and Fellows of Harvard CollegeInventor: Junying Yuan
-
Patent number: 8663663Abstract: The invention relates to transdermal compositions including nifedipine, pentoxifylline, ketamine hydrochloride, gabapentin, lidocaine, and prilocaine that may be used to treat conditions such as circulatory disorders and peripheral neuropathy. Additionally, methods of the invention are directed to treating conditions such as circulatory disorders, peripheral neuropathy, wound healing, blood flow issues, or the like, comprising the steps of transdermal or topical administration of the compositions.Type: GrantFiled: June 10, 2013Date of Patent: March 4, 2014Assignee: JCDS Holdings, LLCInventor: Jay Richard Ray, II
-
Publication number: 20140057910Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.Type: ApplicationFiled: February 22, 2012Publication date: February 27, 2014Applicant: Schering CorporationInventors: Zhaoning Zhu, Brian McKittrick, Zhong-Yue Sun, Yuanzan C. Ye, Johannes H. Voight, Corey Strickland, Elizabeth M. Smith, Andrew W. Stamford, William J. Greenlee, Robert Mazzola, John Caldwell, Jared N. Cumming, Lingyan Wang, Yusheng Wu, Ulrich Iserloh, Tao Guo, Thuy X.H. Le, Kurt W. Saionz, Suresh D. Babu, Rachael C. Hunter
-
Patent number: 8648105Abstract: The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.Type: GrantFiled: December 21, 2011Date of Patent: February 11, 2014Assignee: The Regents of the University of CaliforniaInventors: Michael E. Jung, Dongwon Yoo, Charles L. Sawyers, Chris Tran, John Wongvipat
-
Publication number: 20140031341Abstract: An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRPs), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology.Type: ApplicationFiled: December 19, 2011Publication date: January 30, 2014Applicants: UNIVERSITAT MUNSTER, GALDERMA RESEARCH & DEVELOPMENTInventors: Jerome Aubert, Martin Steinhoff
-
Publication number: 20140024598Abstract: Provided are methods and compositions for maintaining the viability of retinal ganglion cells in a subject with an ocular disorder including, for example, glaucoma and optic nerve injury. The viability of the retinal ganglion cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells and/or promote axon regeneration, thereby minimizing the loss of vision or visual function associated with the ocular disorder.Type: ApplicationFiled: October 21, 2011Publication date: January 23, 2014Inventors: Demetrios Vavvas, Joan W. Miller, Maki Kayama
-
Publication number: 20140023727Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an oxidizing biocide, and its use for the control of microorganisms in aqueous and water-containing systems.Type: ApplicationFiled: March 12, 2012Publication date: January 23, 2014Applicant: DOW GLOBAL TECHNOLOGIES LLCInventors: Freddie L. Singleton, Bei Yin
-
Publication number: 20140024657Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I)-(VIII) and by Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70). These necrostatins are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring necrostatins. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.Type: ApplicationFiled: September 20, 2013Publication date: January 23, 2014Applicant: President and Fellows of Harvard CollegeInventors: Junying YUAN, Emily S. Hsu
-
Publication number: 20140017290Abstract: This invention provides a process for the N-halogenation of at least one 5-hydrocarbyl hydantoin and/or at least one 5,5-dihydrocarbyl hydantoin. The process comprises concurrently feeding into a reaction zone (i) water, inorganic base, and 5,5-dimethylhydantoin, these being fed separately and/or in any combination(s), (ii) a separate feed of a brominating agent, and (iii) a separate feed of a chlorinating agent, in proportions such that during all or substantially all of the time the concurrent feeding is occurring halogenation of the 5-hydrocarbyl hydantoin and/or 5,5-dihydrocarbyl hydantoin occurs and resultant halogenated product precipitates in the liquid phase of an aqueous reaction mixture, and in which the pH of the liquid phase is continuously or substantially continuously maintained in the range of about 2.0 to about 8.0 during all or substantially all of the time the concurrent feeding is occurring.Type: ApplicationFiled: September 19, 2013Publication date: January 16, 2014Applicant: ALBEMARLE CORPORATIONInventor: Hassan Y. Elnagar
-
Patent number: 8628788Abstract: Novel formulations containing a non-oxidative biocide, such as DBNPA, and a source of an in situ produced active biocide, such as a concentrated aqueous solution of an inorganic halide salt, are disclosed. These novel formulations are particularly effective in the treatment of water, and are characterized by high stability, desirable rheological properties and an excellent biocidal activity.Type: GrantFiled: February 25, 2007Date of Patent: January 14, 2014Assignee: Bromine Compounds, Ltd.Inventors: David Feldman, Michel Adda, Raymond J. Roccon
-
Publication number: 20130338116Abstract: The present invention relates generally to pharmaceutical agents, and in particular, to metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of dual acting MMP-2 and MMP-9 inhibiting compounds that exhibit increased potency, metabolic stability and/or reduced toxicity in relation to currently known MMP-2 and MMP-9 inhibitors for the treatment of pain and other diseases. Additionally, the present invention relates to methods for treating pain, addiction and/or withdrawal symptoms in a patient comprising administering to the patient a pain-reducing effective amount of a present compound.Type: ApplicationFiled: August 16, 2013Publication date: December 19, 2013Inventor: Irving Sucholeiki
-
Publication number: 20130338177Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I), wherein variables A1, A3, A4, A5, A6, A8, L, R2, R7, R9, W and Y of Formula (I) are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to plaque formation and deposition, resulting from the activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), sub-Formula embodiments of Formulas (I), (II) and (III), intermediates and processes and methods useful for the preparation of compounds of Formulae (I-III).Type: ApplicationFiled: November 18, 2011Publication date: December 19, 2013Applicant: AMGEN INC.Inventors: Ana Elena Minatti, Oleg Epstein, Ryan White, Matthew Weiss, Wenge Zhong, Jonathan D. Low
-
Patent number: 8604072Abstract: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.Type: GrantFiled: January 19, 2012Date of Patent: December 10, 2013Assignee: Lyotropic Therapeutics, Inc.Inventors: David Anderson, Benjamin G. Cameransi, Jr., Vincent M. Conklin
-
Publication number: 20130324545Abstract: AKR1B1 (EC 1.1.1.21) is an aldose reductase that has mainly been associated with the polyol pathway, and more recently with lipid deperoxidation. We have discovered that the primary activity of this enzyme is rather a PGFS activity, catalyzing the transformation of PGH2 into PGF2?. AKR1B1 as a therapeutic target, and method for modulating its expression and activity are provided. Methods for regulating the expression and activity of PGF2? are also provided.Type: ApplicationFiled: July 17, 2013Publication date: December 5, 2013Applicant: UNIVERSITE LAVALInventors: Michael Fortier, Pierre Chapdelaine, Eva Bresson, Éric Madore
-
Publication number: 20130289050Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.Type: ApplicationFiled: March 4, 2013Publication date: October 31, 2013Applicants: VITAE PHARMACEUTICALS, INC., BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Boehringer Ingelheim International GmbH, Vitae Pharmaceuticals, Inc.
-
Patent number: 8552023Abstract: The present invention is directed to novel non-amidic linkers with branched termini derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.Type: GrantFiled: August 11, 2009Date of Patent: October 8, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Michael R. Wood, June J. Kim, Harold G. Selnick, Shawn J. Stachel
-
Patent number: 8541458Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.Type: GrantFiled: June 11, 2012Date of Patent: September 24, 2013Assignee: Lixte Biotechnology, Inc.Inventors: John S. Kovach, Francis Johnson
-
Publication number: 20130243847Abstract: Creatinine, creatinine precursors or the pharmaceutically acceptable salts thereof are activated to function as an antibacterial agent which has broad spectrum activity and is beneficially used in a variety of applications, such as antimicrobial wound dressings, compositions for topical delivery of the antibacterial agent and for preventing and/or inhibiting the occurrence or spread of bacterial infection, as well as the growth of odor-causing bacteria, to name a few.Type: ApplicationFiled: May 1, 2013Publication date: September 19, 2013Applicant: Board of Regents of the University of NebraskaInventors: Thomas McDonald, Steven Tracy, Annika Weber
-
Patent number: 8536212Abstract: The present invention provides a protective agent for retinal nerve or optic nerve which exerts its effect through a different mechanism from that of conventional therapeutic agents and can be taken for long periods. The present invention is the protective agent for retinal nerve or optic nerve which comprises a compound with aldose reductase inhibiting activity such as the compound represented by the following general formula as an active ingredient. A preferable compound thereof is (2S,4S)-6-fluoro-2?,5?-dioxospiro[chroman-4,4?-imidazolidine]-2-carboxamide: wherein X represents a halogen atom or a hydrogen atom, R1 and R2 independently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto, or optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle.Type: GrantFiled: January 30, 2008Date of Patent: September 17, 2013Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Sookja Kim Chung, Stephen Chung, Chihiro Hibi
-
Patent number: 8524755Abstract: Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.Type: GrantFiled: February 24, 2010Date of Patent: September 3, 2013Assignee: Medivation Prostate Therapeutics, Inc.Inventors: Rajendra Parasmal Jain, Jacqueline A. Gibbons
-
Publication number: 20130217720Abstract: The present invention relates to novel imidazolidine-2,4-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2 (FPR2).Type: ApplicationFiled: February 12, 2013Publication date: August 22, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Patent number: 8496920Abstract: Novel acrylamide and methacrylamide hydantoin monomers which can be reacted with other acrylamide, methacrylamide, acrylate, and methacrylate monomers to form copolymers, which upon halogenation, provide oxidative coatings which are biocidal for use with various materials including, but not limited to, textiles, filters, and latex paints.Type: GrantFiled: October 11, 2011Date of Patent: July 30, 2013Assignee: Auburn UniversityInventors: Shelby D. Worley, Royall M. Broughton, Hasan B. Kocer, Idris Cerkez
-
Patent number: 8492419Abstract: Solid formulations for use in water conditioning of circulating reservoirs, processes of preparing same and methods for water conditioning utilizing same are disclosed. The solid formulations combine a sanitizer with a bath salt and/or an odoriferous substance.Type: GrantFiled: April 25, 2007Date of Patent: July 23, 2013Assignee: Bromine Compounds Ltd.Inventors: David Feldman, Theodore M. Fishler, Amiram Groweiss, Aharon Weissman, Gideon Shikolsky, Moshe Link
-
Patent number: 8487115Abstract: An ester compound represented by formula (1): wherein R3 represents hydrogen or methyl, R4 represents hydrogen or C1-C4 alkyl, and R5 represents hydrogen or C1-C4 alkyl; has an excellent pest control effect and is therefore useful as an active ingredient of a pest control agent.Type: GrantFiled: March 18, 2011Date of Patent: July 16, 2013Assignee: Sumitomo Chemical Company, LimitedInventor: Noritada Matsuo
-
Patent number: 8476454Abstract: Compounds, compositions and methods for the treatment of malignancy are disclosed.Type: GrantFiled: April 13, 2010Date of Patent: July 2, 2013Assignee: Lankenau Institute for Medical ResearchInventors: George C. Prendergast, Alexander J. Muller, James B. Duhadaway, William Malachowski
-
Publication number: 20130149354Abstract: An elastomeric article, such as a glove or a condom, is coated with a compound containing silicone, collagen and allantoin.Type: ApplicationFiled: February 5, 2013Publication date: June 13, 2013Applicants: Xela Corporation, Precision Components, Inc.Inventors: Precision Components, Inc., Xela Corporation
-
Publication number: 20130129839Abstract: Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1, N-oxides, and salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined in the disclosure; and (b) at least one additional fungicidal compound. Also disclosed is a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Formula 1, an N-oxide, or salt thereof (e.g., as a component in the aforesaid composition). Also disclosed is a composition comprising: (a) at least one compound selected from the compounds of Formula 1 described above, N-oxides, and salts thereof; and at least one invertebrate pest control compound or agent.Type: ApplicationFiled: September 1, 2011Publication date: May 23, 2013Applicant: E I DU PONT DE NEMOURS AND COMPANYInventors: Jeffrey Keith Long, Vann Gregory, Steven Gutteridge, Andrew Edmund Taggi, James Francis Bereznak
-
Publication number: 20130129843Abstract: Methods of controlling bacterial, yeast, and/or mold contamination of edible fruits or vegetables comprise applying thereto an aqueous microbiocidal composition formed from water and (A) at least one component selected from (I) a solid-state microbiocidal compound having at least one bromine atom per molecule; (II) an aqueous solution/slurry of a compound of (I); (III) a concentrated aqueous composition having an active bromine content of at least 50,000 ppm derived from water and (i) BrCl or BrCl and Br2 and (ii) overbased alkali metal sulfamate, where the relative proportions of (i) and (ii) give an atom ratio of nitrogen to active bromine greater than 0.93, and where the pH of the composition is greater than 7; and (IV) a solid-state composition formed by dewatering a composition of (III).Type: ApplicationFiled: January 11, 2013Publication date: May 23, 2013Applicant: Albemarle CorporationInventor: Albemarle Corporation
-
Publication number: 20130109731Abstract: An antimicrobial composition comprising water, an organic acid such as citric acid, chitosan, and one or more heterocyclic N-halamine compounds such as MDMH and/or DMDMH.Type: ApplicationFiled: November 1, 2011Publication date: May 2, 2013Applicant: BioMed Protect, LLCInventors: Howard S. Rosing, Ronald I. Pass
-
Publication number: 20130101683Abstract: The invention is directed to compositions and methods of their use as effective biocidal agents for water streams. The composition comprises a halogen source, halogen stabilizers containing a sulfur bearing species and ammonium salts/urea, and an alkali. The sulfur bearing species includes sulfamic acid or its salt equivalent. By having optimized mixing ratio of halogen to stabilizer and that of ammonium salts to sulfamic acid or sulfamate, a synergistic effect occurs which both increases the efficacy of the composition as a biocide and it avoids adverse impacts on other chemicals that are present in the water stream. Best of all the composition is easy to form and easy to introduce into a water stream of concern. Its introduction can be as simple as mixing two containers of reagent prior to introduction to the water process stream.Type: ApplicationFiled: November 4, 2011Publication date: April 25, 2013Applicant: NALCO COMPANYInventors: Wen Li TU, Laura E. RICE, Andrew J. COOPER, Elisa M. LUTH, Yu-mei LU, Jian Kun SHEN
-
Patent number: 8426456Abstract: A composition for treating fungus infection of turfgrass, such as snow mold infection, comprises a mixture of fungicidally effective amounts of formulae 1 and 2: and in particular mixtures of iprodione and trifloxystrobin. A method for treating snow molds comprises applying the mixture before the onset of continuous snow cover, in at least one application.Type: GrantFiled: October 19, 2005Date of Patent: April 23, 2013Assignee: Bayer Cropscience Inc.Inventor: Edwin Vandenberg
-
Patent number: 8420683Abstract: The present invention relates to 5-substituted hydantoins, a process for the preparation of 5-substituted hydantoins and the use of 5-substituted hydantoins in the preparation of enantiomerically enriched ?-amino acids. Furthermore, the present invention relates to the preparation of pharmaceutically active products such as perindopril and ramipril using the novel 5-substituted hydantoins.Type: GrantFiled: June 3, 2008Date of Patent: April 16, 2013Assignee: DSM Sinochem Pharmaceuticals Netherlands B.V.Inventors: Georgios Sarakinos, Wilhelmus Hubertus Joseph Boesten, Dennis Heemskerk, Ben De Lange
-
Publication number: 20130090363Abstract: An ester compound represented by formula (1): wherein R3 represents hydrogen or methyl, R4 represents hydrogen or C1-C4 alkyl, and R5 represents hydrogen or C1-C4 alkyl; has an excellent pest control effect and is therefore useful as an active ingredient of a pest control agent.Type: ApplicationFiled: March 18, 2011Publication date: April 11, 2013Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventor: Noritada Matsuo
-
Publication number: 20130065897Abstract: The present invention provides novel compounds of the Formula I, pharmaceutical compositions comprising such compounds and methods for using such compounds as agents or drugs for inhibiting perforin activity and for treating a subject at risk of or susceptible to a disease or disorder, or having a disease or disorder associated with undesirable perforin activity.Type: ApplicationFiled: December 22, 2010Publication date: March 14, 2013Applicant: PETER MACCALLUM CANCER INSTITUTEInventors: Julie Ann Spicer, Kristiina Maria Huttunen, Dani Michelle Lyons, Joseph Albert Trapani, Mark John Smyth, William Alexander Denny
-
Patent number: 8377979Abstract: The present invention relates to a novel pharmaceutical formulation comprising phenytoin sodium, a high amount of magnesium stearate, and a low level of a hydrophilic polymer such as a methocel, and a method of preparing the same by blending.Type: GrantFiled: December 5, 2006Date of Patent: February 19, 2013Assignee: Taro Pharmaceuticals North America, Inc.Inventors: Tamar Blumberg, Orit Brodzsky, Nataly Zissman, Avraham Yacobi
-
Publication number: 20130040951Abstract: A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has a superior activity as an estrogen-related receptor-? modulator, and is useful as a prophylactic or therapeutic agent for cancer.Type: ApplicationFiled: August 4, 2010Publication date: February 14, 2013Inventors: Atsushi Hasuoka, Koji Ono, Masanori Kawasaki
-
Patent number: 8372876Abstract: A method for improving memory in healthy subjects is disclosed. This method makes use of melatonin receptor antagonists such as luzindole and/or K-185 to reverse the inhibitory effect of melatonin. This invention is particularly relevant among subjects that do not show signs of central nervous system disorders and wish to improve their cognitive performance, especially in tasks.Type: GrantFiled: March 6, 2008Date of Patent: February 12, 2013Assignee: The University of Houston SystemInventors: Gregory M. Cahill, Oliver Rawashdeh
-
Publication number: 20130028966Abstract: The invention provides compounds represented by the formulae: (I) and (II) where the compounds are useful in treating, for example, viral and/or parasitic infections. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds.Type: ApplicationFiled: April 13, 2011Publication date: January 31, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Benhur Lee, Michael E. Jung, Jihye Lee, Frederic Vigant, Peter J. Bradley, Michael C. Wolf, Bettina E. Hajagos
-
Publication number: 20130023529Abstract: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma.Type: ApplicationFiled: July 11, 2012Publication date: January 24, 2013Applicant: The Board of Regents of the University of Texas SystemInventors: Satish K. Srivastava, Kota V. Ramana
-
Publication number: 20130022644Abstract: Compounds of general Formula (I), and cosmetic and pharmaceutical compositions including such a compound are described.Type: ApplicationFiled: February 26, 2010Publication date: January 24, 2013Inventors: Jean-Claude Pascal, Cédric Poinsard
-
Publication number: 20130005698Abstract: A pharmaceutical for preventing or treating an inner ear disorder, comprising a spirohydantoin derivative represented by a general formula (I): in the formula, X represents a halogen atom or a hydrogen atom, and R1 and R2 simultaneously or individually represent a hydrogen atom or an optionally substituted C1-6 alkyl group, or a pharmacologically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: April 25, 2011Publication date: January 3, 2013Applicants: University of Tsukuba, Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Akira Hara, Keiji Tabuchi, Chihiro Hibi
-
Publication number: 20120328569Abstract: Disclosed are compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.Type: ApplicationFiled: March 2, 2011Publication date: December 27, 2012Inventors: Casey Cameron McComas, Nigel J. Liverton, Richard Soll, Peng Li, Xuanjia Peng, Hao Wu, Frank Narjes, Joerg Habermann, Uwe Koch, Shilan Liu
-
Publication number: 20120309803Abstract: An ester compound represented by formula (1): wherein R1 represents C1-C4 alkyl, has an excellent pest control effect and is therefore useful as an active ingredient of a pest control agent.Type: ApplicationFiled: February 18, 2011Publication date: December 6, 2012Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventor: Noritada Matsuo
-
Patent number: 8324259Abstract: A composition for treating fungus infection of turfgrass, such as snow mould infection, comprises a mixture of fungicidally effective amounts of formulae 1 and 2: and in particular mixtures of iprodione and trifloxystrobin. A method for treating snow moulds comprises applying the mixture before the onset of continuous snow cover, in at least one application.Type: GrantFiled: February 10, 2011Date of Patent: December 4, 2012Assignee: Bayer Cropscience Inc.Inventor: Edwin Vandenberg
-
Publication number: 20120301478Abstract: A pharmaceutical for preventing or treating a disorder accompanied by ocular angiogenesis and/or increased ocular vascular permeability, constituted by a combination of an anti-VEGF agent, and a hydantoin derivative represented by a general formula (I): (in the formula, X represents a halogen atom or a hydrogen atom, and R1 and R2 simultaneously or individually represent a hydrogen atom or an optionally substituted C1-6 alkyl group), or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: January 13, 2011Publication date: November 29, 2012Inventors: Yuichiro Ogura, Miho Nozaki, Atsushi Nakajima, Chihiro Hibi
-
Publication number: 20120282307Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.Type: ApplicationFiled: July 19, 2012Publication date: November 8, 2012Applicant: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
-
Publication number: 20120277276Abstract: In the growing of crops for consumption, a method for the removal of pathogens includes the addition to irrigation water for the crops of an anti-pathogen composition and supplying the anti-pathogen composition to the crops prior to harvest while normal irrigation is effected. The anti-pathogen composition is based on halogens, such as chlorine, bromine and iodine, or mixtures of halogens or halogens combined with other organic radicals including cyanurate, hydantoin, peroxide and chlorine dioxide. BCDMH and TICA are preferred anti-pathogen components of the anti-pathogen composition and may be added to a carrier concentrate and measured and dosed into the irrigation water.Type: ApplicationFiled: May 7, 2012Publication date: November 1, 2012Inventors: William Bliss, Sandra Bliss